More specifically, secondary analyses of the UNIFI trial indicated that IL-22 responsive genes indeed regulated neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy (28), potentially relating to the results highlighted here in nonresponders. This evidence concerns the gene IL22 and ulcerative colitis.